Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara
Background: Prostate-specific membrane antigen PET/CT (PSMA PET/CT) has become a cornerstone in the imaging of prostate cancer (PCa), supported by growing evidence and international guideline endorsements. However, real-world adoption and clinical integration of PSMA PET/CT in Italy remain poorly characterised. Methods: A multidisciplinary national cross-sectional survey was developed and distributed between November 4–29, 2024, with endorsement from six major Italian scientific societies. The survey included 93 questions addressing availability, technical aspects, clinical use across disease phases, and professional practices. Separate sections were tailored to clinicians and nuclear medicine physicians. Results: A total of 238 validated responses were analysed (169 clinicians, 69 nuclear medicine physicians). Nuclear medicine respondents were affiliated mainly with high-volume centres, while clinicians reported greater variability in institutional access. PSMA PET/CT was perceived as insufficiently available by 58% of clinicians at the institutional level, with 36.1% stating that waiting times led to changes in imaging strategy. [68Ga]Ga-PSMA-11 was the preferred tracer among clinicians (57.4%), while nuclear medicine physicians expressed more balanced preferences driven by logistics. Divergent views also emerged regarding the clinical relevance of biodistribution differences. For primary staging, PSMA PET/CT was used by 50% of clinicians for high-risk patients and by 20% for intermediate-risk patients, whereas 87% of nuclear medicine physicians identified PSMA PET/CT as the optimal imaging modality for intermediate-to-high-risk PCa. In cases of discordant imaging findings, multidisciplinary discussion was the preferred strategy for resolution. Conclusion: Access to, usage of, and perceptions about PSMA PET/CT differ between clinicians and nuclear medicine physicians, highlighting the need for improved availability and enhanced interdisciplinary coordination.
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: technical aspects and primary staging setting
Background: Prostate-specific membrane antigen PET/CT (PSMA PET/CT) has become a cornerstone in the imaging of prostate cancer (PCa), supported by growing evidence and international guideline endorsements. However, real-world adoption and clinical integration of PSMA PET/CT in Italy remain poorly characterised. Methods: A multidisciplinary national cross-sectional survey was developed and distributed between November 4–29, 2024, with endorsement from six major Italian scientific societies. The survey included 93 questions addressing availability, technical aspects, clinical use across disease phases, and professional practices. Separate sections were tailored to clinicians and nuclear medicine physicians. Results: A total of 238 validated responses were analysed (169 clinicians, 69 nuclear medicine physicians). Nuclear medicine respondents were affiliated mainly with high-volume centres, while clinicians reported greater variability in institutional access. PSMA PET/CT was perceived as insufficiently available by 58% of clinicians at the institutional level, with 36.1% stating that waiting times led to changes in imaging strategy. [68Ga]Ga-PSMA-11 was the preferred tracer among clinicians (57.4%), while nuclear medicine physicians expressed more balanced preferences driven by logistics. Divergent views also emerged regarding the clinical relevance of biodistribution differences. For primary staging, PSMA PET/CT was used by 50% of clinicians for high-risk patients and by 20% for intermediate-risk patients, whereas 87% of nuclear medicine physicians identified PSMA PET/CT as the optimal imaging modality for intermediate-to-high-risk PCa. In cases of discordant imaging findings, multidisciplinary discussion was the preferred strategy for resolution. Conclusion: Access to, usage of, and perceptions about PSMA PET/CT differ between clinicians and nuclear medicine physicians, highlighting the need for improved availability and enhanced interdisciplinary coordination.
Bauckneht, Matteo; Evangelista, Laura; Sofia, Luca; Maccauro, Marco; Filice, Angelina; De Rimini, Maria Luisa; Caffo, Orazio; Messina, Carlo; Maruzzo,...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2612850
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Citazioni
ND
0
ND
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.